Overview

Ph1 FIH Dose-escalation and Dose-expansion Study of BMF-219, in Adult Patients With Acute Leukemia

Status:
Recruiting
Trial end date:
2023-06-21
Target enrollment:
Participant gender:
Summary
Phase1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Irreversible Menin Inhibitor, in Adult Patients With Acute Leukemia
Phase:
Phase 1
Details
Lead Sponsor:
Biomea Fusion